First quarter biopharma dealmaking continues where it left off last year
One might think that with the current white hot biopharma initial public offering (IPO) market – which has prevailed during the early months of 2014 – private company boards and senior management have been spending all their time mulling over whether they should follow in the footsteps of the 28 firms that already made this successful leap, collectively raising $2.2 billion in the process.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST